Liproxstatin-1 is a potent and selective inhibitor of ferroptosis (IC50=22 nM). Liproxstatin-1 protects cells from ferroptosis induced by ferroptosis inducers (e.g., Erastin, RSL3).

Ferroptosis:22 nM

METHODS: Mouse fibroblasts L929 were treated with Liproxstatin-1 (0-250 nM) for 24 h. Cell viability was measured using AquaBluer.
RESULTS: Liproxstatin-1 protected against FINs such as BSO (10 μM), erastin (1 μM), and RSL3 (0.5 μM) in a dose-dependent manner, while it did not rescue staurosporine (0.2 μM) or H2O2 (200 μM)-induced cell death. [1]
METHODS: Oligodendrocytes OLN93 were treated with Liproxstatin-1 (1 μM) and RSL-3 (7.89 μM) for 24 h, and GSH levels were measured by micro reduced GSH assay kit.
RESULTS: Liproxstatin-1 treatment increased GSH levels compared to the RSL-3 group. [2]

METHODS: To test the potential to prevent animal-induced Gpx4 destruction in vivo, Liproxstatin-1 (10 mg/kg) was administered intraperitoneally to TAM-treated CreERT2;Gpx4fl/fl mice once daily for two weeks.
RESULTS: Liproxstatin-1 significantly prolonged survival. the number of TUNEL+ cells in the Liproxstatin-1 group was significantly reduced, and the table Liproxstatin-1 delayed the desmoplasia of renal tubular cells. [1]
METHODS: To investigate the role of ferroptosis in inflammation-associated cognitive deficits, Liproxstatin-1 (10 mg/kg) was administered intraperitoneally to C57BL/6 mice once daily for five days followed by LPS administration.
RESULTS: Liproxstatin-1 ameliorated memory deficits in a mouse model of LPS-induced cognitive impairment.The protective effects of Liproxstatin-1 were associated with attenuation of iron deposition and modulation of the iron-death-associated protein families, TF, xCT, Fth, Gpx4 and FtMt. [3]

Cell viability is assessed at different time points after treatment using AquaBluer according to the manufacturer’s recommendations. Alternatively, cell death is also quantified by measuring released lactate dehydrogenase activity using the cytotoxicity detection kit (LDH). (Only for Reference)